Literature DB >> 20161047

Role of Imaging in Prostate Cancer.

Hossein Jadvar, Abass Alavi.   

Abstract

Entities:  

Year:  2009        PMID： 20161047      PMCID： PMC2746671          DOI： 10.1016/j.cpet.2009.05.003

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


× No keyword cloud information.
  50 in total

1.  Prognostic factors in hormone-resistant progressing cancer of the prostate.

Authors:  S D Fosså; D P Dearnaley; M Law; J Gad; D W Newling; K Tveter
Journal:  Ann Oncol       Date:  1992-05       Impact factor: 32.976

Review 2.  Rising PSA after a radical treatment.

Authors:  P Carroll
Journal:  Eur Urol       Date:  2001       Impact factor: 20.096

3.  The role of computed tomography in evaluation of skeletal metastases.

Authors:  M Rafii; H Firooznia; E Kramer; C Golimbu; J Sanger
Journal:  J Comput Tomogr       Date:  1988-01

Review 4.  Prostate-specific membrane antigen.

Authors:  W R Fair; R S Israeli; W D Heston
Journal:  Prostate       Date:  1997-07-01       Impact factor: 4.104

Review 5.  Metastatic prostate cancer: assessment of response to systemic therapy.

Authors:  R Dreicer
Journal:  Semin Urol Oncol       Date:  1997-02

Review 6.  The prostate: diagnostic evaluation of metastatic disease.

Authors:  K K Yu; R A Hawkins
Journal:  Radiol Clin North Am       Date:  2000-01       Impact factor: 2.303

Review 7.  The role of prostate-specific antigen in the chemoprevention of prostate cancer.

Authors:  E D Crawford; E P DeAntoni; C A Ross
Journal:  J Cell Biochem Suppl       Date:  1996

Review 8.  Imaging for prostate cancer.

Authors:  B M Carey
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-10       Impact factor: 4.126

Review 9.  How to use prostate-specific antigen.

Authors:  N R Ploch; M K Brawer
Journal:  Urology       Date:  1994-02       Impact factor: 2.649

10.  "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer.

Authors:  Aisha Lofters; Helen G Juffs; Gregory R Pond; Ian F Tannock
Journal:  J Urol       Date:  2002-12       Impact factor: 7.450
View more
  5 in total

1.  Influence of (11)C-choline PET/CT on radiotherapy planning in prostate cancer.

Authors:  Escarlata López; Antonio Lazo; Antonio Gutiérrez; Gregorio Arregui; Isabel Núñez; Antonio Sacchetti
Journal:  Rep Pract Oncol Radiother       Date:  2014-12-16

Review 2.  Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2010-12-13       Impact factor: 10.057

3.  Role of ¹¹C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation.

Authors:  Francesco Bertagna; Muhannad Abuhilal; Giovanni Bosio; Claudio Simeone; Pierluigi Rossini; Claudio Pizzocaro; Emanuela Orlando; Marco Finamanti; Giorgio Biasiotto; Carlo Rodella; Sergio Cosciani Cunico; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2011-07-24       Impact factor: 2.374

4.  Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake.

Authors:  David M Schuster; Pooneh A Taleghani; Peter T Nieh; Viraj A Master; Rianot Amzat; Bital Savir-Baruch; Raghuveer K Halkar; Tim Fox; Adeboye O Osunkoya; Carlos S Moreno; Jonathon A Nye; Weiping Yu; Baowei Fei; Zhibo Wang; Zhengjia Chen; Mark M Goodman
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-01-05

5.  Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer.

Authors:  Niki Marie Zacharias; Christopher McCullough; Sriram Shanmugavelandy; Jaehyuk Lee; Youngbok Lee; Prasanta Dutta; James McHenry; Linda Nguyen; William Norton; Lawrence W Jones; Pratip K Bhattacharya
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.